Environmental, Social And Governance (ESG) Report

Overview

The report presents Abbisko's 2025 ESG performance across governance, environmental management, employee development and community initiatives. The company reports RMB 612.1 million in total revenue and the approval of its first self-developed innovative drug, pimicotinib. ESG oversight is assigned to the Board, supported by an ESG working team, while 276 employees and 100% training coverage are reported. The Group also reports 1,651.88 tCO2e from Scopes 1 and 2 and 2,086.36 tCO2e from Scopes 1, 2 and 3.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services